Fukuoka, Japan

Kenji Kabashima

This inventor holds 1 USPTO granted patent and 7 published patent applications and 1 EPO patent. Top assignees: Hamamatsu University School of Medicine, Ono Pharmaceutical Co., Ltd.. Active years: 2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kenji Kabashima. Retrieved from https://idiyas.com/inventor/kenji-kabashima

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kenji Kabashima: Innovator in Skin Tissue Abnormality Treatment

Introduction

Kenji Kabashima is an inventor based in Kyoto-shi, Kyoto, Japan. He has made significant contributions to the field of dermatology, particularly in the treatment of skin tissue abnormalities. Although he currently holds no granted patents, his work is noteworthy for its potential impact on medical science.

Latest Patent Applications

Kenji Kabashima's latest patent application is titled "Composition for Ameliorating Skin Tissue Abnormality." This application presents a composition aimed at improving skin tissue abnormalities, comprising a compound of formula (I) or an ester, oxide, pharmaceutically acceptable salt, or solvate thereof. This innovative approach could pave the way for new treatments in dermatology.

Conclusion

Kenji Kabashima's work in developing compositions for skin tissue abnormalities highlights his dedication to advancing medical treatments. His contributions, although not yet reflected in granted patents, demonstrate the potential for future innovations in this important field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…